微出血与不明来源栓塞性卒中抗凝效果:NAVIGATE ESUS 探索性分析
该研究为 NAVIGATE ESUS 随机临床试验的探索性亚组分析,纳入 3699 例有基线磁共振微出血信息的 ESUS 患者,比较利伐沙班与阿司匹林疗效。微出血患病率 11%,与复发卒中、脑出血及全因死亡风险升高相关,但未发现微出血与治疗分配存在交互作用。
要点
- ESUS 患者中微出血患病率 11%,与高血压、多 Territory 梗死等相关。
- 微出血与复发卒中风险 1.5 倍、脑出血风险 4.2 倍及死亡风险 2.1 倍相关。
- 微出血未显著改变利伐沙班与阿司匹林对临床结局的相对效应。
核心结论
- 微出血标志 ESUS 患者复发卒中、缺血性卒中、脑出血及死亡风险升高,但不影响利伐沙班对临床结局的效应。
研究设计与样本
- 研究覆盖 31 个国家 459 个卒中中心,共 7213 例 NAVIGATE ESUS 参与者,其中 3699 例(51%)有基线临床磁共振微出血信息并纳入本分析。
- 纳入标准为年龄≥50 岁、筛查前 7 天至 6 个月内神经影像确诊的 ESUS;有症状性脑出血病史者被排除。
主要发现
- 3699 例参与者中 395 例(11%)存在微出血;微出血患者平均(SD)年龄 69.5(9.4)岁,男性 241 例(61%),白人 201 例(51%)。
- 与微出血独立相关的因素包括:年龄增长(每岁 OR 1.03;95%CI 1.01-1.04)、东亚种族/族裔(OR 1.57;95%CI 1.04-2.37)、高血压(OR 2.20;95%CI 1.54-3.15)、多 Territory 梗死(OR 1.95;95%CI 1.42-2.67)、陈旧性梗死(OR 1.78;95%CI 1.42-2.23)及隐匿性脑出血(OR 5.23;95%CI 2.76-9.90)。
- 微出血与复发卒中风险升高 1.5 倍相关(HR 1.5;95%CI 1.0-2.3),与脑出血风险升高 4 倍相关(HR 4.2;95%CI 1.3-13.9),与全因死亡风险升高 2 倍相关(HR 2.1;95%CI 1.1-4.3);严格脑叶微出血与缺血性卒中风险升高约 2.5 倍相关(HR 2.3;95%CI 1.3-4.3)。
临床怎么用
- 对于 ESUS 患者,基线磁共振发现微出血提示复发卒中、脑出血及死亡风险较高,应加强风险分层与随访。
- 微出血的存在未显著改变利伐沙班与阿司匹林疗效比较,抗凝决策仍需结合个体出血风险综合评估。
局限性
- 本研究为探索性亚组分析,仅 51% 的 NAVIGATE ESUS 参与者有微出血信息,可能存在选择偏倚。
- 微出血评估基于基线临床磁共振报告,未采用统一序列或中心判读,可能存在信息偏倚。
- 有症状性脑出血病史者被排除,限制了结果外推至该人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The reported associations of cerebral microbleeds with recurrent stroke and intracerebral hemorrhage have raised concerns regarding antithrombotic treatment in patients with a history of stroke and microbleeds on magnetic resonance imaging. OBJECTIVE: To characterize microbleeds in embolic strokes of undetermined source (ESUS) and report interactions between microbleeds and the effects of random assignment to anticoagulant vs antiplatelet therapy. DESIGN, SETTING, AND PARTICIPANTS: Subgroup analyses of the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs Aspirin to Prevent Embolism in ESUS (NAVIGATE ESUS) international, double-blind, randomized, event-driven phase 3 clinical trial. Participants were enrolled between December 2014 and September 2017 and followed up for a median of 11 months. The study setting included 459 stroke recruitment centers in 31 countries. Patients aged 50 years or older who had neuroimaging-confirmed ESUS between 7 days and 6 months before screening were eligible. Of these 7213 NAVIGATE ESUS participants, 3699 (51%) had information on cerebral microbleeds reported on their baseline clinical magnetic resonance imaging and were eligible for these analyses. Patients with a prior history of symptomatic intracerebral hemorrhage were excluded from the NAVIGATE ESUS trial. INTERVENTIONS: Rivaroxaban, 15 mg, compared with aspirin, 100 mg, daily. MAIN OUTCOMES AND MEASURES: The primary outcome was recurrent stroke. Secondary outcomes were ischemic stroke, intracerebral hemorrhage, and all-cause mortality. RESULTS: Microbleeds were present in 395 of 3699 participants (11%). Of patients with cerebral microbleeds, mean (SD) age was 69.5 (9.4) years, 241 were men (61%), and 201 were White (51%). Advancing age (odds ratio [OR] per year, 1.03; 95% CI, 1.01-1.04), East Asian race/ethnicity (OR, 1.57; 95% CI, 1.04-2.37), hypertension (OR, 2.20; 95% CI, 1.54-3.15), multiterritorial infarcts (OR, 1.95; 95% CI, 1.42-2.67), chronic infarcts (OR, 1.78; 95% CI, 1.42-2.23), and occult intracerebral hemorrhage (OR, 5.23; 95% CI, 2.76-9.90) were independently associated with microbleeds. The presence of microbleeds was associated with a 1.5-fold increased risk of recurrent stroke (hazard ratio [HR], 1.5; 95% CI, 1.0-2.3), a 4-fold risk of intracerebral hemorrhage (HR, 4.2; 95% CI, 1.3-13.9), a 2-fold risk of all-cause mortality (HR, 2.1; 95% CI, 1.1-4.3), and strictly lobar microbleeds with an approximately 2.5-fold risk of ischemic stroke (HR, 2.3; 95% CI, 1.3-4.3). There were no interactions between microbleeds and treatment assignments for recurrent stroke, ischemic stroke, or all-cause mortality. The HR of intracerebral hemorrhage on rivaroxaban was similar between persons with microbleeds (HR, 3.1; 95% CI, 0.3-30.0) and persons without microbleeds (HR, 3.0; 95% CI, 0.6-14.7; interaction P = .97). CONCLUSIONS AND RELEVANCE: Microbleeds mark an increased risk of recurrent stroke, ischemic stroke, intracerebral hemorrhage, and mortality in ESUS but do not appear to influence effects of rivaroxaban on clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02313909.
引用
- Shoamanesh A, Hart RG, Connolly SJ, et al. Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 33074284. doi:10.1001/jamaneurol.2020.3836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。